Data V.15.9690
Site data
Field Value
Name pharma.bayer.nl
URL pharma.bayer.nl
Country Netherlands
Division Pharma health
Block Consumer
User data
Field Value
Title Mister
First name Tjerk
Last name Geersing
Email tjerk.geersing@healthbase.nl
Phone 0630379175
Consumer data
Field Value
Theme Pulmonale arteriƫle hypertensie (PAH)
Theme email helenede.kruijs@bayer.com
Question, remark or suggestion Geachte, In de SPC van Riociguat staat onderstaande informatie. Kloppen de genoemde percentages (53%, 139% or 54%). Het lijkt vreemd dat <30 mL/min de riociguat plasmaconcentratie minder toeneemt dan bij een creatinine klaring 30-50 mL/min. Moet het bijvoorbeeld niet 154% zijn? Vriendelijke groet, Tjerk Geersing Apotheker medicatiebewaking Health Base 5.2 Renal impairment Overall, mean dose- and weight- normalised exposure values for riociguat were higher in subjects with renal impairment compared to subjects with normal renal function. Corresponding values for the main metabolite were higher in subjects with renal impairment compared to healthy subjects. In nonsmoking individuals with mild (creatinine clearance 80-50 mL/min), moderate (creatinine clearance <50-30 mL/min) or severe (creatinine clearance <30 mL/min) renal impairment, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively. Data in patients with creatinine clearance <30 mL/min are limited and there are no data for patients on dialysis. Due to the high plasma protein binding riociguat is not expected to be dialysable.